ReviewExpert review of vaccines2017
Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.
Review in Expert review of vaccines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 51 citations in OpenAlex.
- Article
- Article
- An integrated computational antigen discovery pipeline with hierarchical filtering for emerging viral variants.NAR molecular medicine · 2026Article
- Article
- Attenuated viral strains of priority pathogens for potential use in controlled human infection model studies: A scoping review.PLoS neglected tropical diseases · 2026Article
- Recent advances in treatment and detection of Rift Valley fever virus: a comprehensive overview.Virus genes · 2025Review
- Rift Valley fever outbreak among animal handlers in Kinyogoga Village, Nakaseke District, Central Uganda: A case study.PLOS global public health · 2025Article
- The Rift Valley fever (RVF) vaccine candidate 40Fp8 shows an extreme attenuation in IFNARKO mice following intranasal inoculation.PLoS neglected tropical diseases · 2024Article
- Evaluation of a Combined Live Attenuated Vaccine against Lumpy Skin Disease, Contagious Bovine Pleuropneumonia and Rift Valley Fever.Vaccines · 2024Article
- Can the Revolution in mRNA-Based Vaccine Technologies Solve the Intractable Health Issues of Current Ruminant Production Systems?Vaccines · 2024Review
- Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates.NPJ vaccines · 2023Review
- Article
- Safety and immunogenicity of inactivated Rift Valley Fever Smithburn viral vaccine in sheep.Virology journal · 2023Article
- Rift Valley Fever Virus-Infection, Pathogenesis and Host Immune Responses.Pathogens (Basel, Switzerland) · 2023Review
- A Countrywide Seroepidemiological Survey of Rift Valley Fever in Livestock, Uganda, 2017.The American journal of tropical medicine and hygiene · 2023Article
- Determining the acceptability of a novel One Health vaccine for Rift Valley Fever prior to phase II/III clinical trials in Uganda.One health (Amsterdam, Netherlands) · 2023Article
- Rift Valley Fever Virus Primes Immune Responses inPathogens (Basel, Switzerland) · 2023Article
- Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use.Vaccines · 2023Review
- Immunogenicity of a Candidate Live Attenuated Vaccine for Rift Valley Fever Virus with a Two-Segmented Genome.Viral immunology · 2023Article
- Pseudotyped Viruses for Phlebovirus.Advances in experimental medicine and biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
introductionRift Valley fever (RVF) is a mosquito-borne zoonotic viral disease endemic to Africa and the Arabian Peninsula. High rates of abortion among infected ruminants and hemorrhagic fever in infected humans are major public health concerns. Commercially available veterinary RVF vaccines are important for preventing the spread of the Rift Valley fever virus (RVFV) in endemic countries; however, RVFV outbreaks continue to occur frequently in endemic countries in the 21st century. In the U.S., the live-attenuated MP-12 vaccine has been developed for both animal and human vaccination. This vaccine strain is well attenuated, and a single dose induces neutralizing antibodies in both ruminants and humans. Areas covered: This review describes scientific evidences of MP-12 vaccine efficacy and safety, as well as MP-12 variants recently developed by reverse genetics, in comparison with other RVF vaccines. Expert commentary: The containment of active RVF outbreaks and long-term protection from RVF exposure to infected mosquitoes are important goals for RVF vaccination. MP-12 vaccine will allow immediate vaccination of susceptible animals in case of an unexpected RVF outbreak in the U.S., whereas MP-12 vaccine may be also useful for the RVF control in endemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.